Polycystic liver disease: a clinical review

Polycystic liver disease rarely occurs in isolation as part of autosomal dominant polycystic liver disease, but more commonly, it exists as an extra-renal manifestation of autosomal dominant polycystic kidney disease. The pathogenesis of polycystic liver disease involves defects in the primary ciliu...

Full description

Bibliographic Details
Main Author: Natasha Chandok, M.D., MPH, FRCPC
Format: Article
Language:English
Published: Elsevier 2012-11-01
Series:Annals of Hepatology
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1665268119314061
id doaj-92b435d329f64d43a3fec3e9ab340600
record_format Article
spelling doaj-92b435d329f64d43a3fec3e9ab3406002021-06-09T05:54:30ZengElsevierAnnals of Hepatology1665-26812012-11-01116819826Polycystic liver disease: a clinical reviewNatasha Chandok, M.D., MPH, FRCPC0Correspondence and reprint request:; Department of Medicine, Multi-Organ Transplant Program, Western University, London, Ontario, CanadaPolycystic liver disease rarely occurs in isolation as part of autosomal dominant polycystic liver disease, but more commonly, it exists as an extra-renal manifestation of autosomal dominant polycystic kidney disease. The pathogenesis of polycystic liver disease involves defects in the primary cilium of the cholangiocyte, with genetic mutations that impair key proteins integral to the complex functioning of cilia. While most patients are asymptomatic and require no intervention aside from reassurance and genetic counseling, in a minority of patients, polycystic liver disease creates a myriad of symptoms from the compressive effects of enlarged cysts, and can even cause malnutrition and liver decompensation in the severest of cases. In patients with symptomatic disease, a variety of interventional radiology or surgical techniques can be considered, including aspiration with sclerotherapy of a dominant cyst, fenestration, segmental hepatic resection, and even liver transplantation. Although there are no curative medical options for polycystic liver disease, somatostatin analogs hold promise and have shown minimal efficacy in human studies. However, further research is needed to develop more efficacious medical treatments.http://www.sciencedirect.com/science/article/pii/S1665268119314061Polycystic liver diseaseCystsTreatment
collection DOAJ
language English
format Article
sources DOAJ
author Natasha Chandok, M.D., MPH, FRCPC
spellingShingle Natasha Chandok, M.D., MPH, FRCPC
Polycystic liver disease: a clinical review
Annals of Hepatology
Polycystic liver disease
Cysts
Treatment
author_facet Natasha Chandok, M.D., MPH, FRCPC
author_sort Natasha Chandok, M.D., MPH, FRCPC
title Polycystic liver disease: a clinical review
title_short Polycystic liver disease: a clinical review
title_full Polycystic liver disease: a clinical review
title_fullStr Polycystic liver disease: a clinical review
title_full_unstemmed Polycystic liver disease: a clinical review
title_sort polycystic liver disease: a clinical review
publisher Elsevier
series Annals of Hepatology
issn 1665-2681
publishDate 2012-11-01
description Polycystic liver disease rarely occurs in isolation as part of autosomal dominant polycystic liver disease, but more commonly, it exists as an extra-renal manifestation of autosomal dominant polycystic kidney disease. The pathogenesis of polycystic liver disease involves defects in the primary cilium of the cholangiocyte, with genetic mutations that impair key proteins integral to the complex functioning of cilia. While most patients are asymptomatic and require no intervention aside from reassurance and genetic counseling, in a minority of patients, polycystic liver disease creates a myriad of symptoms from the compressive effects of enlarged cysts, and can even cause malnutrition and liver decompensation in the severest of cases. In patients with symptomatic disease, a variety of interventional radiology or surgical techniques can be considered, including aspiration with sclerotherapy of a dominant cyst, fenestration, segmental hepatic resection, and even liver transplantation. Although there are no curative medical options for polycystic liver disease, somatostatin analogs hold promise and have shown minimal efficacy in human studies. However, further research is needed to develop more efficacious medical treatments.
topic Polycystic liver disease
Cysts
Treatment
url http://www.sciencedirect.com/science/article/pii/S1665268119314061
work_keys_str_mv AT natashachandokmdmphfrcpc polycysticliverdiseaseaclinicalreview
_version_ 1721388738283569152